Israeli Company Receives FDA Nod for Its New Treatment for Psychiatric Mood Disorders and Opioid Addiction

A Jerusalem-based company, BrainsWay, has obtained FDA approval for its non-invasive treatment for Major Depressive Disorder (MDD) and Obsessive Compulsive Disorder (OCD). BrainsWay specializes in the use of electromagnetic waves to target and stimulate the parts of the brain that are responsible for mood disorders. The company previously released its Deep Transcranial Magnetic Stimulation System, which was designed to treat MDD, and has now taken their technology further via the advent of a special H-coil helmet that will enable the transcranial electromagnetic waves to further penetrate the brain and treat OCD. This upgrade, which will also be integrated into existing Deep TMS Systems, is streamlined to improve the experience of both the doctor and the patient, and has enhanced features such as a patient management system and rapid motor threshold detection.

The company is studying the application of its technology for use in treating individuals with other psychiatric disorders as well, who would also like to reduce reliance on traditional medications and their undesirable side effects. In particular, BrainsWay was tapped by the FDA to join an exclusive collaboration with seven other hand-picked companies to incorporate its Deep TMS research into a device that will help control the epidemic misuse and overdose of prescription opioids.